EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer

Pawel Rajwa, Piotr Zapała, Axel S Merseburger

European Urology Focus · 2025

DOI: 10.1016/j.euf.2024.07.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2025. Verfasst von Pawel Rajwa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University of Silesia, Zabrze, Poland; Department of Urology, Comprehensive Cancer Center, Medical University of Vienn…. Hauptthemen laut MEDLINE: Receptors, Androgen, Androgen Receptor Antagonists, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There have been significant advances in our understanding of the biology of metastatic prostate cancer (mPCa) and its response to therapy. Androgen receptor (AR) alterations, including mutations, amplifications, splice variants, and alternative activations, play a significant role in mPCa resistance to treatment. Recent studies indicate that AR alterations detected via genomic testing can be considered predictive biomarkers in men with castration-resistant PCa and can guide treatment strategies. Novel therapeutic approaches, including AR antagonists and inhibitors of ACK1, the AR N-terminal domain, or cytochrome P450 11A1, have shown promise in overcoming treatment resistance. Ongoing clinical trials are exploring the efficacy of these treatments in relation to AR mutation status and could potentially transform the treatment landscape for mPCa. PATIENT SUMMARY: Our mini review highlights advances in the treatment of metastatic prostate cancer, with a focus on drugs that target genetic alterations affecting a protein called the androgen receptor. Some promising results have been obtained and clinical trials are ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenAndrogen Receptor AntagonistsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleNeoplasm MetastasisMutationMolecular Targeted TherapyDrug Resistance, Neoplasm

Stichwörter der Autor:innen

AlterationsAndrogen receptorCastration resistantProstate cancer

Substanzen

Receptors, AndrogenAndrogen Receptor AntagonistsAR protein, human

Autor:innen und Institutionen

  • Department of Urology, Medical University of Silesia, Zabrze, Poland; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany. Electronic address: axel.merseburger@uksh.de.

Zitieren

APA

Rajwa, P., Zapała, P., & Merseburger, A. S. (2025). Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2024.07.012

Vancouver

Rajwa P, Zapała P, Merseburger AS. Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer. European Urology Focus. 2025. doi:10.1016/j.euf.2024.07.012

BibTeX
@article{Rajwa2025,
  author = {Rajwa, Pawel and Zapała, Piotr and Merseburger, Axel S},
  title = {Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer},
  journal = {European Urology Focus},
  year = {2025},
  doi = {10.1016/j.euf.2024.07.012}
}
Kostenlos starten →